BioAtla and GATC initiate SPV transaction to bolster the ongoing study

Announcement

BioAtla, Inc., a leading clinical-level biotechnology company focusing on the establishment of Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has joined hands with GATC Health Corp. (GATC). GATC is a well-known tech-bio company accelerating artificial intelligence (AI) to bring transition and flourish the development and drug discovery. The two organisations have declared the SPV transaction to upgrade ozuriftamab vedotin (Oz-V) (CAB-ROR2-ADC) in a convincing Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma (OPSCC).

Transaction knocks on the development door

SPV will envelop an initial $5 million for operational work and 2L+ OPSCC clinical trial expenses from Inversagen AI, LLC. Inversagen is a new company all set to treat age-based disease and is known for its origin from GATC Health Corp. The difference is that Inversagen holds an advanced license (authority) to BioAtla’s longevity technologies and CAB senescence. Alongside, the GATC has exclusive license rights to senescence robust AI longevity technologies.

The primary completion of the SPV transaction will be visible simultaneously with the official confirmed closing of Inversagen AI, LLC’s financing decisions. The announcement might come in a fraction by 30th January 2026, with the other pending $35 million expected to shut later in Q1 2026. The time when Oz-V registrational clinical study will be in a state to start working on all case subjects, adhering to the completion of financing structure by the customary closing conditions and Inversagen AI, LLC.

Later, this company will get a place in Oz-V with an estimated 35% of ownership stake. Whereas, BioAtla will continue its 65% ownership throughout each Oz-V solid tumor indication on successful completion of the transaction. GATC and BioAtla Health are planning to partner with Inversagen AI to strengthen the research and development space of CAB senolytic therapies, while BioAtla will stick to the rights regarding the cancer therapeutic applications of these best-in-class new therapies.

Co-founder, Chief Executive Officer, and Chairman of BioAtla, Inc., PhD, Jay M. Short, said, “We are thrilled to bring this collaboration to the forefront for upgrading Oz-V into a Phase 3 development for the patients suffering from OPSCC. This innovative single-asset financing form doubles our equity value for our loyal shareholders. We have a smart registrational approach with the capability to secure speedy approval in the US and a step to implement the Phase 3 pivotal trial, which is in ‘to-do’ list in early 2026.”